输卵管癌 | Medical guideline

首页 肿瘤学指南  输卵管癌

输卵管癌

按发表年份

The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

 2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 输卵管癌

 Japan Society of Gynecologic Oncology

The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely (1) Overview of the Guidelines (2) Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Recurrent Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (4) Borderline Epithelial Tumors of the Ovary (5) Malignant Germ Cell Tumors of the Ovary and (6) Malignant Sex Cord-stromal Tumors. Furthermore the Guidelines Comprise 5 Algorithms-namely (1) Initial Treatment for Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (2) Treatment for Recurrent Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Initial Treatment for Borderline Epithelial Ovarian Tumor (4) Treatment for Malignant Germ Cell Tumor and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer" (2) Involvement of Patients and General (male/female) Participants in Addition to Physicians Pharmacists and Nurses (3) Clinical Questions (CQs) in the PICO Format (4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System (5) Introduction of the Idea of a Body of Evidence (6) Categorization of References According to Research Design (7) Performance of Systematic Reviews and Meta-analysis for Three CQs and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

 2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

 Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Niraparib for Maintenance Treatment of Advanced Ovarian, Fallopian Tube and Peritoneal Cancer after Response to First-line Platinum-based Chemotherapy

 2021年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 National Institute for Health and Care Excellence

指南简介 原文链接
Olaparib plus Bevacizumab for Maintenance Treatment of Advanced Ovarian, Fallopian Tube Or Primary Peritoneal Cancer

 2021年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 National Institute for Health and Care Excellence

指南简介 原文链接
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer

 2021年发布于 National Comprehensive Cancer Network 所属人体系统：生殖 | 输卵管癌

 National Comprehensive Cancer Network

指南简介 原文链接
Olaparib for Maintenance Treatment of Relapsed Platinum-sensitive Ovarian, Fallopian Tube Or Peritoneal Cancer

 2020年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 National Institute for Health and Care Excellence

指南简介 原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man

 2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 输卵管癌

 FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique) Au CNGOF (Collège National Des Gynécologues Obstétriciens Français) À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).

Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert a Subjective Analysis Is Optimal. If Performed by a Non-expert Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert) a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian Fallopian Tube Or Primary Peritoneal Cancer It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2 Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency GFR <30mL/min) an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3 Grade C). by Analogy the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3 Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3 Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa

 2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 输卵管癌

 FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). Adjuvant Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancers (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete 6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended Or a Discussion with the Patient About Intraperitoneal Chemotherapy According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介 原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Long Text of the Joint French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa. Part 1: Diagnostic Exploration and Staging, Surgery, Perioperative Care, and Pathology

 2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 输卵管癌

 FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN) Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF) La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)

An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (grade A). in Presumed Early-stage Ovarian Or Tubal Cancers the Following Procedures Should Be Performed: an Omentectomy (at a Minimum Infracolic) an Appendectomy Multiple Peritoneal Biopsies Peritoneal Cytology (grade C) and Pelvic and Para-aortic Lymphadenectomies (grade B) for All Histologic Types Except the Expansile Mucinous Subtypes for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer When There Is No Risk of Tumor Rupture (grade B). for FIGO Stages III Or IV Ovarian Tubal and Primary Peritoneal Cancers a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (grade B) as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e. Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian Tubal Or Primary Peritoneal Cancer (grade B). for Advanced Cancers Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B).
指南简介 原文链接
Rucaparib for Maintenance Treatment of Relapsed Platinum-sensitive Ovarian, Fallopian Tube Or Peritoneal Cancer

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 National Institute for Health and Care Excellence

指南简介 原文链接
Olaparib for Maintenance Treatment of BRCA Mutation-positive Advanced Ovarian, Fallopian Tube Or Peritoneal Cancer after Response to First-line Platinum-based Chemotherapy

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 National Institute for Health and Care Excellence

指南简介 原文链接
Niraparib for Maintenance Treatment of Relapsed, Platinum-sensitive Ovarian, Fallopian Tube and Peritoneal Cancer

 2018年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 National Institute for Health and Care Excellence

指南简介 原文链接

人体系统

 2021年 发布于 Journal of Gynecologic Oncology 32卷 第2期 所属人体系统： 生殖 | 输卵管癌

 Japan Society of Gynecologic Oncology

 2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 输卵管癌

 Ontario Health (Cancer Care Ontario)

 2021年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 输卵管癌

 National Institute for Health and Care Excellence

 2021年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 输卵管癌

 National Institute for Health and Care Excellence

 2021年 发布于 National Comprehensive Cancer Network 所属人体系统： 生殖 | 输卵管癌

 National Comprehensive Cancer Network

 2020年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 输卵管癌

 National Institute for Health and Care Excellence

 2019年 发布于 Gynecol Obstet Fertil Senol 47卷 第2期 所属人体系统： 生殖 | 输卵管癌

 2019年 发布于 Eur J Obstet Gynecol Reprod Biol 236卷 第_期 所属人体系统： 生殖 | 输卵管癌

 2019年 发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷 第6期 所属人体系统： 生殖 | 输卵管癌

 2019年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 输卵管癌

 National Institute for Health and Care Excellence

 2019年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 输卵管癌

 National Institute for Health and Care Excellence

 2018年 发布于 National Institute for Health and Care Excellence 所属人体系统： 生殖 | 输卵管癌

 National Institute for Health and Care Excellence

 2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 输卵管癌

 2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

 2021年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 2021年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 2021年发布于 National Comprehensive Cancer Network 所属人体系统：生殖 | 输卵管癌

 2020年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 2019年发布于 Gynecol Obstet Fertil Senol 47卷第2期 所属人体系统：生殖 | 输卵管癌

 2019年发布于 Eur J Obstet Gynecol Reprod Biol 236卷第_期 所属人体系统：生殖 | 输卵管癌

 2019年发布于 Journal of Gynecology Obstetrics and Human Reproduction 48卷第6期 所属人体系统：生殖 | 输卵管癌

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 2019年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌

 2018年发布于 National Institute for Health and Care Excellence 所属人体系统：生殖 | 输卵管癌